Search alternatives:
non decrease » nn decrease (Expand Search), point decrease (Expand Search), note decreased (Expand Search)
ng decrease » nn decrease (Expand Search), _ decrease (Expand Search), gy decreased (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), mean decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 non » _ non (Expand Search), a non (Expand Search), i non (Expand Search)
Showing 1,041 - 1,060 results of 100,555 for search '(( 5 non decrease ) OR ( 5 ((((ng decrease) OR (a decrease))) OR (we decrease)) ))', query time: 1.44s Refine Results
  1. 1041
    Source data for S5 Fig numerical data.

    Source data for S5 Fig numerical data. by Erienne G. Norton (9612079)

    Published 2025
    Save to List
    Saved in:
  2. 1042
    Source data for Fig 5 numerical data.

    Source data for Fig 5 numerical data. by Erienne G. Norton (9612079)

    Published 2025
    Save to List
    Saved in:
  3. 1043
    Synthesis and Antiproliferative Activity of a New Series of Mono- and Bis(dimethylpyrazolyl)‑<i>s</i>‑triazine Derivatives Targeting EGFR/PI3K/AKT/mTOR Signaling Cascades

    Synthesis and Antiproliferative Activity of a New Series of Mono- and Bis(dimethylpyrazolyl)‑<i>s</i>‑triazine Derivatives Targeting EGFR/PI3K/AKT/mTOR Signaling Cascades by Ihab Shawish (13015516)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  4. 1044
    Synthesis and Antiproliferative Activity of a New Series of Mono- and Bis(dimethylpyrazolyl)‑<i>s</i>‑triazine Derivatives Targeting EGFR/PI3K/AKT/mTOR Signaling Cascades

    Synthesis and Antiproliferative Activity of a New Series of Mono- and Bis(dimethylpyrazolyl)‑<i>s</i>‑triazine Derivatives Targeting EGFR/PI3K/AKT/mTOR Signaling Cascades by Ihab Shawish (13015516)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  5. 1045
    Rac and PKB activities are required for a late phase of cerebellar LTP.

    Rac and PKB activities are required for a late phase of cerebellar LTP. by Claire Jackson (362873)

    Published 2010
    “…<p><b>A</b>) Addition of the Rac inhibitor EHT1864 (50 µM; n = 7) to pipette solution decreases LTP duration. …”
    Save to List
    Saved in:
  6. 1046
    Demographics and baseline characteristics of the safety population.

    Demographics and baseline characteristics of the safety population. by Rahsan Erdem (11726357)

    Published 2021
    Subjects:
    Save to List
    Saved in:
  7. 1047
    iOWH032 inhibits cholera toxin-induced secretion in a mouse closed-loop model.

    iOWH032 inhibits cholera toxin-induced secretion in a mouse closed-loop model. by Rahsan Erdem (11726357)

    Published 2021
    Subjects:
    Save to List
    Saved in:
  8. 1048
    Grading of stool consistency and diarrhea severity.

    Grading of stool consistency and diarrhea severity. by Rahsan Erdem (11726357)

    Published 2021
    Subjects:
    Save to List
    Saved in:
  9. 1049
    Secondary efficacy endpoints for the modified intent-to-treat population.

    Secondary efficacy endpoints for the modified intent-to-treat population. by Rahsan Erdem (11726357)

    Published 2021
    Subjects:
    Save to List
    Saved in:
  10. 1050
    Study drug–related treatment-emergent adverse events by system organ class and preferred term in the safety population.

    Study drug–related treatment-emergent adverse events by system organ class and preferred term in the safety population. by Rahsan Erdem (11726357)

    Published 2021
    Subjects:
    Save to List
    Saved in:
  11. 1051
    Source data for Fig 1.

    Source data for Fig 1. by Rahsan Erdem (11726357)

    Published 2021
    Subjects:
    Save to List
    Saved in:
  12. 1052
    Diarrheal stool output rate overall and by blood type status in the modified intent-to-treat population.

    Diarrheal stool output rate overall and by blood type status in the modified intent-to-treat population. by Rahsan Erdem (11726357)

    Published 2021
    Subjects:
    Save to List
    Saved in:
  13. 1053
    Source data for S1 and S2 Figs.

    Source data for S1 and S2 Figs. by Rahsan Erdem (11726357)

    Published 2021
    Subjects:
    Save to List
    Saved in:
  14. 1054
    Source data for Fig 2.

    Source data for Fig 2. by Rahsan Erdem (11726357)

    Published 2021
    Subjects:
    Save to List
    Saved in:
  15. 1055
    Consolidated Standards for Reporting of Trials flow diagram.

    Consolidated Standards for Reporting of Trials flow diagram. by Rahsan Erdem (11726357)

    Published 2021
    Subjects:
    Save to List
    Saved in:
  16. 1056
    iOWH032 inhibits cholera toxin-induced fecal output in a cecectomized rat model.

    iOWH032 inhibits cholera toxin-induced fecal output in a cecectomized rat model. by Rahsan Erdem (11726357)

    Published 2021
    Subjects:
    Save to List
    Saved in:
  17. 1057
    Source data for Fig 3.

    Source data for Fig 3. by Rahsan Erdem (11726357)

    Published 2021
    Subjects:
    Save to List
    Saved in:
  18. 1058
    Scatterplot of iOWH032 plasma concentrations versus diarrheal stool output rate.

    Scatterplot of iOWH032 plasma concentrations versus diarrheal stool output rate. by Rahsan Erdem (11726357)

    Published 2021
    Subjects:
    Save to List
    Saved in:
  19. 1059
    Reverse cumulative distribution plot for diarrheal stool output rate overall in the modified intent-to-treat population.

    Reverse cumulative distribution plot for diarrheal stool output rate overall in the modified intent-to-treat population. by Rahsan Erdem (11726357)

    Published 2021
    Subjects:
    Save to List
    Saved in:
  20. 1060
    Diarrheal disease severity by treatment group for the modified intent-to-treat population.

    Diarrheal disease severity by treatment group for the modified intent-to-treat population. by Rahsan Erdem (11726357)

    Published 2021
    Subjects:
    Save to List
    Saved in:

Search Tools: